Alterity Therapeutics Ltd (ATHE) stock
ATHENasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as PRNAF
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Jun 30, 2026Last filing: 20-F on Aug 28, 2026Score 5/30
$1.86−0.09 (-4.85%)
Close on Nov 17, 2026Market cap $33.80MP/E –Yield –
Alterity Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2026 it was A$17.63M, up 22.4% from the year before. Over ten years it grew 6.3% a year on average. The highest annual figure on record is A$18.64M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | A$17.63M | +22.4% |
| FY2025 | Jun 30, 2025 | A$14.40M | -22.7% |
| FY2024 | Jun 30, 2024 | A$18.64M | +41.3% |
| FY2023 | Jun 30, 2023 | A$13.20M | -10.5% |
| FY2022 | Jun 30, 2022 | A$14.75M | +20.0% |
| FY2021 | Jun 30, 2021 | A$12.28M | +21.6% |
| FY2020 | Jun 30, 2020 | A$10.10M | -22.2% |
| FY2019 | Jun 30, 2019 | A$12.98M | +93.8% |
| FY2018 | Jun 30, 2018 | A$6.70M | +17.5% |
| FY2017 | Jun 30, 2017 | A$5.70M | -40.5% |
| FY2016 | Jun 30, 2016 | A$9.59M | – |
See a number that looks wrong?